Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

Mon, 20 Jul 2026 08:00:00 -0400

Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT

FLORHAM PARK, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, July 30, 2026, to report its second quarter 2026 financial results and provide a business update.

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

Mon, 20 Jul 2026 08:00:00 -0400

Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at

Form 4 Phathom Pharmaceuticals, For: Jul 14 Filed by: Breedlove Robert Charles

Thu, 16 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260716/26780073.html

Form 4 Phathom Pharmaceuticals, For: Jul 14 Filed by: Breedlove Robert Charles

Thu, 16 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260716/26780073.html

Form 8-K Phathom Pharmaceuticals, For: Jun 23

Tue, 23 Jun 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260623/26676124.html

Form 8-K Phathom Pharmaceuticals, For: Jun 23

Tue, 23 Jun 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260623/26676124.html

Phathom completes enrollment in Phase 2 EoE trial of Voquezna

Tue, 23 Jun 2026 07:59:13 -0400

Phathom Pharmaceuticals (Nasdaq: PHAT) announced it has completed patient enrollment in its Phase 2 pHalcon-EoE-201 clinical trial, which is evaluating VOQUEZNA (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults. The company said enrollment was completed ahead of schedule.

The study enrolled 95 adults with endoscopically confirmed EoE and dysphagia across 41 U.S. sites. Participants were randomized evenly to receive either VOQUEZNA 20 mg or placebo once daily for 12 weeks in the double-blind portion of the trial. Patients completing that phase may enter a 12-week open-label extension in which all participants receive VOQUEZNA 20 mg once daily.

Topline

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Tue, 23 Jun 2026 07:59:00 -0400

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE
Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026

FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA^® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults. The study has enrolled 95 patients at

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Tue, 23 Jun 2026 07:59:00 -0400

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE
Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026

H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)

Wed, 17 Jun 2026 06:50:54 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $26.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT).

The analyst commented: "This past week, we hosted our H.C. Wainwright KOL Investor Webinar available here, with an interventional gastroenterologist offering clinical perspectives on VOQUEZNA and decade-long patient experience including the treatment of erosive esophagitis, non-erosive GERD, and H. pylori infection. We specifically discussed the KOL’s utilization of Phathom’s FDA-approved first-in-class novel potassium competitive acid blocker (PCAB), VOQUEZNA (vonoprazan), as the first innovation in decades in the GERD space targeting heartburn relief associated with non-erosive GERD (NERD), the healing and maintenance of healing

Form 4 Phathom Pharmaceuticals, For: May 22 Filed by: Parikh Asit

Wed, 27 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26558391.html

Form 4 Phathom Pharmaceuticals, For: May 22 Filed by: Parikh Asit

Wed, 27 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26558391.html

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Fri, 22 May 2026 08:00:00 -0400

FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in May and June:

Craig-Hallum 23rd Annual Institutional Investor Conference in Minneapolis, MN
Date: Thursday, May 28, 2026
Management to participate in one-on-one meetings throughout the conference

Jefferies Global Healthcare Conference in New York, NY
Date: Wednesday, June 3, 2026
Fireside Chat: 12:15 pm EDT
Management to participate in

StreetInsider.com News Articles

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

Form 4 Phathom Pharmaceuticals, For: Jul 14 Filed by: Breedlove Robert Charles

Form 4 Phathom Pharmaceuticals, For: Jul 14 Filed by: Breedlove Robert Charles

Form 8-K Phathom Pharmaceuticals, For: Jun 23

Form 8-K Phathom Pharmaceuticals, For: Jun 23

Phathom completes enrollment in Phase 2 EoE trial of Voquezna

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)

Form 4 Phathom Pharmaceuticals, For: May 22 Filed by: Parikh Asit

Form 4 Phathom Pharmaceuticals, For: May 22 Filed by: Parikh Asit

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Parikh Asit

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Parikh Asit

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: COLA MICHAEL F

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: COLA MICHAEL F

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Schroeder Theodore R

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Schroeder Theodore R

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: KARBE FRANK

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: KARBE FRANK

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Topper James N

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Topper James N

Form 4 Phathom Pharmaceuticals, For: May 19 Filed by: Stenhouse Mark